While shares of small-cap food biotech Senomyx (NASDAQ:SNMX) have pulled back almost 30% from my last piece as enthusiasm has faded in the wake of securing GRAS determination for key product Sweetmyx S617, they're still up more than 50% from my Top Idea write-up in 2013. More importantly, Senomyx continues to make significant progress with its developmental and commercial programs. Although Senomyx shares may well get batted around this year as the market vacillates between risk-on and risk-off, the significant potential of the company's sweet and savory programs is a good reason to buy or continue holding the shares.
Earnings Are Not A Driver Yet
Senomyx reported second quarter earnings on Thursday, July 31, but the...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|